GHRP-6 vs MK-677: what the comparison videos get wrong

What did @zern.fit actually say?

The creator compared GHRP-6 and MK-677 as growth hormone secretagogues, both working through ghrelin receptor activation. Their main argument: GHRP-6 has a shorter half-life, produces a stronger appetite boost, causes less disruption to glucose metabolism and fluid retention, and better mirrors the body's natural pulsatile growth hormone release. They wrapped up with a standard disclaimer about not being a doctor.

Worth noting immediately: they mispronounced MK-677 as "Ibupinomorn" mid-sentence, which is either a script slip or a case of reading too fast. It doesn't affect the substance of their claims, but it's a tell that this content was produced quickly. The actual name is ibutamoren (also called MK-677 or MK-0677).

Does the science back this up?

On the half-life comparison, the creator is on solid ground. The pharmacokinetics here are well-documented. GHRP-6 has a half-life of roughly 15 to 60 minutes depending on route of administration, while MK-677 has a half-life of approximately 24 hours. That difference is real and clinically significant.

The pulsatile release claim also has genuine support. Growth hormone is secreted in pulses, and GHRP-6's short half-life means GH spikes are more transient and acute, closer to physiological release patterns. A longer-acting compound like MK-677 produces more sustained, elevated GH and IGF-1 levels across the day. Nass et al. (2008, Journal of Clinical Endocrinology and Metabolism) documented this sustained elevation with MK-677 over two years, including associated side effects.

The glucose metabolism claim is where things get more complicated, and the creator undersells how significant that distinction actually is.

What did they get wrong (or right)?

They got the half-life comparison right. They got the pulsatile release point right. Where they stumble is framing GHRP-6 as simply "less impactful" on glucose metabolism compared to MK-677, without flagging that MK-677's glucose disruption is a documented clinical concern, not just a minor footnote.

Nass et al. (2008) found that MK-677 increased fasting blood glucose and insulin resistance in older adults over a two-year trial. That's not a minor difference in side effect profiles. For anyone with pre-diabetes, insulin resistance, or metabolic syndrome, that distinction matters considerably.

On the flip side, GHRP-6 is not without metabolic effects of its own. Murphy et al. (1998, Journal of Clinical Endocrinology and Metabolism) showed GHRP-6 also stimulates cortisol and prolactin alongside GH, which the creator did not mention. Chronically elevated cortisol has its own implications for blood sugar and body composition. Saying GHRP-6 is "less impactful" on glucose is probably accurate in relative terms, but the framing implies GHRP-6 is metabolically clean. That's an overstatement.

The appetite claim is accurate in direction but lacks nuance. Both compounds stimulate appetite through ghrelin receptor agonism, but GHRP-6 is generally considered to produce a more pronounced, acute hunger response due to its rapid pharmacokinetics. This is consistent with clinical observation, though direct head-to-head trials are limited.

What should you actually know?

Neither of these compounds is approved by the FDA for the indications being discussed. MK-677 was studied extensively by Merck as a potential treatment for growth hormone deficiency and muscle wasting, but was never approved. GHRP-6 has been investigated in clinical research but also lacks regulatory approval for general use. That context matters.

The creator's framing of both as "solid options" for appetite struggles glosses over the fact that these are research compounds with incomplete long-term safety data in healthy adults. The comparison the creator is drawing, while directionally reasonable, is based on a mix of clinical pharmacology and bodybuilding community extrapolation. Not all of it comes from controlled trials in the populations who are actually watching this video.

If you are interested in secretagogue therapy for legitimate clinical reasons, such as age-related GH decline or recovery support, that conversation belongs with a licensed provider who can assess your metabolic baseline, not a 60-second TikTok. The disclaimer the creator added at the end is legally appropriate but does not substitute for the missing clinical context throughout the video.

The bottom line on this comparison

The creator got the broad pharmacokinetic comparison right, and the pulsatile release argument is legitimate. But the glucose metabolism framing is too breezy given the documented clinical findings on MK-677, and GHRP-6's cortisol and prolactin effects deserved at least a mention. This is a 6 out of 10 in terms of accuracy, not because the claims are wildly wrong, but because the caveats that matter most are the ones that got left out.